Skip to content
EveryOption

Buprenorphine-naloxone

Learn what this care may do. See what research says. Then check where to get care. A place may not be taking new patients.

Explore for Opioid use disorder

Summary

SAMHSA guidance supports buprenorphine treatment within its retained scope; exact products and local availability require separate evidence.

SAMHSA TIP 63: Medications for Opioid Use Disorder · checked Aug 31, 2026

Relationship: supports bounded summary

Statement scope

Jurisdiction

United States

Population

people with opioid use disorder

Source collection coverage: country:US

Pointer: /conclusion

Open source
Published Aug 31, 2026Revision 11 · EveryOptionEnglish (United States)

Published Need uses

Select an exact Need to inspect its scoped research. These are the uses currently published on EveryOption; they do not establish every use of Buprenorphine-naloxone or a personal recommendation.

1 published use

Buprenorphine-naloxone for Opioid use disorder

The research answer belongs to this exact Need and its published scope. It does not establish benefit for other uses of Buprenorphine-naloxone.

Research suggests benefit in this exact scope

Published Aug 31, 2026 · revision 11

What research says

The retained SAMHSA guidance supports buprenorphine treatment for opioid use disorder while preserving product, personal-suitability, and access boundaries.

SAMHSA TIP 63: Medications for Opioid Use Disorder · checked Aug 31, 2026

Relationship: supports bounded conclusion

Statement scope

Jurisdiction

United States

Population

people with opioid use disorder

Source collection coverage: country:US

Pointer: /conclusion

Open source
SAMHSA TIP 63: Medications for Opioid Use Disorder · checked Aug 31, 2026

Relationship: medication treatment for opioid use disorder

Statement scope

Jurisdiction

United States

Population

people with opioid use disorder

Source collection coverage: country:US

Pointer: /conclusion

Open source
SAMHSA TIP 63: Medications for Opioid Use Disorder · checked Aug 31, 2026

Relationship: medication treatment for opioid use disorder

Statement scope

Jurisdiction

United States

Population

people with opioid use disorder

Source collection coverage: country:US

Pointer: /conclusion

Open source
SAMHSA TIP 63: Medications for Opioid Use Disorder · checked Aug 31, 2026

Relationship: medication treatment for opioid use disorder

Statement scope

Jurisdiction

United States

Population

people with opioid use disorder

Source collection coverage: country:US

Pointer: /conclusion

Open source
SAMHSA TIP 63: Medications for Opioid Use Disorder · checked Aug 30, 2026

Relationship: medication treatment for opioid use disorder

Statement scope

Jurisdiction

United States

Population

people with opioid use disorder

Source collection coverage: country:US

Pointer: /conclusion

Open source
SAMHSA TIP 63: Medications for Opioid Use Disorder · checked Aug 31, 2026

Relationship: medication treatment for opioid use disorder

Statement scope

Jurisdiction

United States

Population

people with opioid use disorder

Source collection coverage: country:US

Pointer: /conclusion

Open source
Read exact answerExplore Opioid use disorder options

Official product records

Product identity and regulator wording are shown in their exact jurisdiction and indication scope. They do not establish that a product is appropriate for you or available from a local provider.

1 active records

  1. SUBOXONE sublingual film

    SUBOXONE sublingual film is indicated for treatment of opioid dependence.

    U.S. Food and Drug Administration · US · prescribing information · current labeling

    Source identity
    NDA 022410 · version current

    Routes
    SUBLINGUAL · BUCCAL

    Open official record

Next: check access

Research and local availability are different facts. Add a place to see known, source-backed access options for Buprenorphine-naloxone.

Find access

See something wrong? Tell us. Your note is private. We check sources before we change this page.